CRA’s Life Sciences Practice was retained by a biotechnology company to perform a valuation of its gene editing patent portfolio, and to provide recommendations regarding potential licensing agreements with other companies. CRA developed a valuation model based on publicly available information relating to market opportunities, potential sales, and various risk factors for products in the field of human therapeutics. In addition to assisting the company in assessing the market potential for the use of the relevant patents in the fields of agriculture and research tools. CRA provided recommendations regarding the optimal royalty structure to include in potential future licensing agreements.
CRA Sessions: AI in Practice | Copyright in the age of AI: Following the evidence
A historic $1.5 billion settlement by Anthropic delivered the first significant judicial ruling on the issue. The ruling is expected to influence how courts,...